US Stock MarketDetailed Quotes
SKYE SKYE BIOSCIENCE INC
- 4.260
- -0.020-0.47%
Close Nov 27 16:00 ET
- 4.260
- 0.0000.00%
Post 16:02 ET
129.24MMarket Cap8.04P/E (TTM)
4.350High4.170Low76.13KVolume4.280Open4.280Pre Close325.04KTurnover0.50%Turnover RatioLossP/E (Static)30.34MShares19.41052wk High1.70P/B64.48MFloat Cap1.73052wk Low--Dividend TTM15.14MShs Float64.725Historical High--Div YieldTTM4.21%Amplitude1.440Historical Low4.269Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
SKYE BIOSCIENCE INC Stock Forum
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Skye Bioscience (Nasdaq: SKYE) has commented on Novo Nordisk's Phase 2a top-line data for monlunabant, a small-molecule oral CB1 inverse agonist. The study met its primary endpoint, showing at least 6% placebo-adjusted weight loss at 16 weeks. However, dose-dependent neuropsychiatric side effects were observed.
Skye highlights the advan...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity. Skye Bioscience (Nasdaq: SKYE) has launched a Phase 2 clinical trial, CBeyond™, to evaluate its peripheral CB1 inhibitor, nimacimab, for weight loss in patients with obesity.
The study will assess nimacimab's efficacy as a monotherapy and in combination with a GLP-1 receptor agonist (Wegovy®). Key aspects of the trial include:
- 12...
$SKYE BIOSCIENCE INC (SKYE.US)$ $Boundless Bio (BOLD.US)$
I had been eyeing this off for a while. Tried to buy in Jan at 0.019-0.020 but then left it alone as for whatever reason I wasn't able to buy.
Now I see it's gone from 0.02000 to a whopping 3.15.
Damn you Mr Market, that's ice cold!
whhhyyyyyyyyyy?!?!?!?!?! 😭😭
No comment yet